Atacand Side Effects
Generic name: candesartan
Note: This document contains side effect information about candesartan. Some of the dosage forms listed on this page may not apply to the brand name Atacand.
Some side effects of Atacand may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to candesartan: oral tablet
Along with its needed effects, candesartan (the active ingredient contained in Atacand) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking candesartan:Rare
- Arm, back, or jaw pain
- bleeding gums
- chest pain or discomfort
- chest tightness or heaviness
- cough or hoarseness
- fast or irregular heartbeat
- joint pain
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- lower back or side pain
- pain or discomfort in the arms, jaw, back, or neck
- painful or difficult urination
- shortness of breath
- swelling of the feet or lower legs
- Abdominal or stomach pain
- black, tarry stools
- bloody urine
- dark urine
- decreased urine output
- difficult or troubled breathing
- general feeling of tiredness or weakness
- hives or welts
- increased blood pressure
- increased thirst
- light-colored stools
- loss of appetite
- muscle pain or cramps
- numbness or tingling in the hands, feet, or lips
- pale skin
- redness of the skin
- skin rash
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- swelling of the face, ankles, or hands
- unusual bleeding or bruising
- unusual tiredness or weakness
- upper right abdominal or stomach pain
- weakness or heaviness of the legs
- weight gain
- yellow eyes or skin
Some side effects of candesartan may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:Less common
- Ear congestion or pain
- head congestion
- runny or stuffy nose
For Healthcare Professionals
Applies to candesartan: oral tablet
In general, candesartan (the active ingredient contained in Atacand) has been well tolerated in large, prospective, placebo-controlled clinical trials. Overall, the rates of withdrawal of therapy due to adverse events among treated versus placebo patients were 3.3% and 3.5%, respectively.
Nervous system side effects have been reported the most frequently. These have included headache (3%) and dizziness. Fatigue, vertigo, and paresthesias have been reported in at least 0.5% of patients.
Cardiovascular side effects including peripheral edema and chest pain have been reported in 1% of patients and at rates similar to placebo. Myocardial infarction and angina pectoris have been reported rarely. Hypotension (18.8% vs. 9.8% in placebo), tachycardia (0.5%), and palpitations (0.5%) have been reported. Rare cases of angioedema have also been reported.
Caution should be observed when initiating therapy in patients with heart failure. Patients with heart failure given candesartan commonly have some reduction in blood pressure. In the CHARM program, the incidence of hypotension leading to drug discontinuation in candesartan-treated patients was 4.1% compared with 2.0% in placebo-treated patients.
Respiratory side effects have included cough, but it has been less frequent with the use of candesartan (the active ingredient contained in Atacand) or other angiotensin II antagonists (reported in approximately 1% of treated patients and placebo patients alike) than with angiotensin converting enzyme inhibitors. Bronchitis, coughing, sinusitis, pharyngitis, upper respiratory tract infection, and dyspnea have been reported in approximately 0.5% to 1.0% of patients. Upper respiratory tract infections have been reported among 6% of treated patients (compared with 4% placebo patients) in controlled clinical trials. These infections have included pharyngitis (2% vs. 1% of patients) and rhinitis (2% vs. 1% of patients). A cause-and-effect relationship is unlikely.
Candesartan did not significantly affect pulmonary function, bronchial hyperreactivity, or cough in patients with asthma.
Gastrointestinal side effects including nausea, vomiting, abdominal pain, and diarrhea have been reported in at least 1% of patients and at rates similar to placebo. Dyspepsia and gastroenteritis have been reported in 0.5% of patients. Alteration of taste sensitivity has also been associated with candesartan (the active ingredient contained in Atacand) use.
Musculoskeletal side effects have included back pain (3%), arthralgias (1%), and myalgias (0.5%). Rarely, rhabdomyolysis have been reported during postmarketing experience in patients receiving angiotensin II receptor blockers.
Endocrinologic side effects have been reported rarely. These have included hyperuricemia, hyperglycemia, hypertriglyceridemia, and elevated plasma creatine phosphokinase in approximately 0.5% of patients.
Hematologic side effects including epistaxis has been reported in 0.5% of patients. Neutropenia, leukopenia, and agranulocytosis have been reported rarely. A causal relationship has not been established.
Psychiatric side effects have been reported rarely. These have included anxiety, depression, and somnolence in approximately 0.5% of patients.
Dermatologic side effects have been reported rarely. These have included rash or increased sweating in approximately 0.5% of patients. Psoriasis development or exacerbation has been reported. Pruritus and urticaria have been reported in postmarketing experience.
Genitourinary side effects including hematuria has been reported in 0.5% of patients. A causal relationship has not been established.
Metabolic side effects have rarely included increased creatine phosphokinase, hyperglycemia, hypertriglyceridemia, hyperuricemia, hyperkalemia, and hyponatremia.
Hepatic side effects have included transient elevations of serum liver transaminases. At least one case of hepatotoxicity with icterus, hepatomegaly, and abnormal liver function tests has been reported.
Renal side effects including renal impairment and renal failure have been reported during postmarketing experience.
Hypersensitivity side effects have been reported rarely. At least one case of acute nephritic syndrome with accompanying pruritic rash has been reported.
Other side effects including asthenia and fever have been reported in approximately 0.5% of patients.
More Atacand resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.